Bill journey · stage 2 of 5
Under committee review
What it doesSummary reported to house (Sep 30, 2022)
This resolution directs the Department of Health and Human Services (HHS) to furnish to the House of Representatives any external or internal communications of the White House regarding the implications of imposing certain penalties on drug manufacturers that do not comply with HHS price negotiations under the Medicare prescription drug benefit.
What just happenedSep 30, 2022
Placed on the House Calendar, Calendar No. 140.
Who’s behind it
Placed on the House Calendar, Calendar No. 140.
Reported adversely by the Committee on Energy and Commerce. H. Rept. 117-534.
Reported adversely by the Committee on Energy and Commerce. H. Rept. 117-534.
Ordered to be Reported Adversely by the Yeas and Nays: 31 - 22.
Committee Consideration and Mark-up Session Held.
Subcommittee on Health Discharged.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
This resolution directs the Department of Health and Human Services (HHS) to furnish to the House of Representatives any external or internal communications of the White House regarding the implications of imposing certain penalties on drug manufacturers that do not comply with HHS price negotiations under the Medicare prescription drug benefit.
This resolution directs the Department of Health and Human Services (HHS) to furnish to the House of Representatives any external or internal communications of the White House regarding the implications of imposing certain penalties on drug manufacturers that do not comply with HHS price negotiations under the Medicare prescription drug benefit.